EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF.
EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF.
复制标题
DOI：
10.18632/oncotarget.2870
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Mourah S
中科院分区：
文献类型：
--
作者：
Khayati F;Pérez-Cano L;Maouche K;Sadoux A;Boutalbi Z;Podgorniak MP;Maskos U;Setterblad N;Janin A;Calvo F;Lebbé C;Menashi S;Fernandez-Recio J;Mourah S
EMMPRIN/CD 147主要以其蛋白酶诱导功能而闻名，但也已证明其在促进肿瘤血管生成中的作用。这项研究提供的证据表明，EMMPRIN是一个新的共同受体的VEGFR-2酪氨酸激酶受体在内皮细胞和肿瘤细胞，因为它直接与它相互作用，并调节其激活的VEGF配体，信号和功能的后果在体外和体内。计算对接分析和诱变研究确定了位于细胞膜附近的EMMPRIN胞外结构域中的分子结合位点，并含有氨基酸195/199。EMMPRIN在癌症中过表达，因此能够进一步增强VEGFR-2活化，表明抗血管生成药物与EMMPRIN/VEGFR-2相互作用抑制剂的联合治疗可能对抑制血管生成和恶性肿瘤具有更大的影响。
EMMPRIN/CD147 is mainly known for its protease inducing function but a role in promoting tumor angiogenesis has also been demonstrated. This study provides evidence that EMMPRIN is a new coreceptor for the VEGFR-2 tyrosine kinase receptor in both endothelial and tumor cells, as it directly interacts with it and regulates its activation by its VEGF ligand, signalling and functional consequences both in vitro and in vivo. Computational docking analyses and mutagenesis studies identified a molecular binding site in the extracellular domain of EMMPRIN located close to the cell membrane and containing the amino acids 195/199. EMMPRIN is overexpressed in cancer and hence is able to further potentiate VEGFR-2 activation, suggesting that a combinatory therapy of an antiangiogenic drug together with an inhibitor of EMMPRIN/VEGFR-2 interaction may have a greater impact on inhibiting angiogenesis and malignancy.
登录
查看更多内容
影响因子：
3.7
作者：
Bougatef F;Menashi S;Khayati F;Naïmi B;Porcher R;Podgorniak MP;Millot G;Janin A;Calvo F;Lebbé C;Mourah S
通讯作者：
Mourah S
影响因子：
56.9
作者：
Naldini, L;Blomer, U;Trono, D
通讯作者：
Trono, D
影响因子：
8
作者：
Shields, J. D.;Emmett, M. S.;Bates, D. O.
通讯作者：
Bates, D. O.
影响因子：
5.3
作者：
Hyde, Caroline A. C.;Giese, Alexandra;Ballmer-Hofer, Kurt
通讯作者：
Ballmer-Hofer, Kurt
影响因子：
2.9
作者：
Chen, R;Li, L;Weng, ZP
通讯作者：
Weng, ZP